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It is well established that adrenal stress hormone-induced activa-
tion of the basolateral complex of the amygdala (BLA) influences
memory consolidation. The present experiments investigated the
involvement of corticotropin-releasing hormone (CRH) in the BLA
in modulating memory consolidation. Bilateral infusions of the CRH
receptor antagonist [9–41]--helical CRH (0.3, 1.0, or 3.0 g in 0.2
l) administered into the BLA of male Sprague–Dawley rats im-
mediately after aversively motivated inhibitory avoidance training
produced dose-dependent impairment of 48-h retention perfor-
mance. Because the CRH receptor antagonist infusions did not
impair retention when administered into the BLA 3 h after training,
the retention impairment selectively was due to time-dependent
influences on memory consolidation. Furthermore, because imme-
diate posttraining infusions of [9–41]--helical CRH into the adja-
cent central nucleus of the amygdala (CEA) were ineffective, the
effect selectively involved the BLA. Immunocytochemistry showed
that the aversive training stimulus of a single, brief footshock
increased CRH levels in the CEA. These findings indicate that
activation of CRH receptors in the BLA, likely by training-induced
release of endogenous peptide originating from the CEA, partici-
pates in mediating stress effects on memory consolidation.
CRF  CRH  inhibitory avoidance  memory storage  neuropeptide
Enhanced long-term memory for stressful or emotionallyarousing experiences is well documented. Likely mechanisms
for acute stress effects on long-term memory include signaling
processes induced by stressful challenges, including those of
adrenal stress hormones and various neurotransmitters (1–3). It
is well established that the stress-responsive neuropeptide
corticotropin-releasing hormone (CRH) not only acts as a key
neuroendocrine stress mediator, initiating activation of the
hypothalamic–pituitary–adrenocortical axis (4, 5), but also di-
rectly modulates neuronal activity in several limbic regions (6, 7).
CRH influences on learning and memory have been reported in
studies of animal (8–15) and human subjects (16).
The basolateral complex of the amygdala (BLA, consisting of
the basal, lateral, and accessory basal nuclei) is critically involved
in mediating emotional arousal and stress hormone effects on
memory consolidation (3, 17–19). The BLA contains a large
population of projection neurons bearing CRH receptors (20,
21). The finding that infusions of CRH administered into the
whole amygdala after training enhance inhibitory avoidance
retention (22) clearly implicates the amygdala in mediating CRH
effects on memory consolidation. However, studies have not yet
determined whether such effects are due to activation of CRH
receptors in the BLA. This is critical, because the central nucleus
of the amygdala (CEA) also contains CRH receptors (20, 23)
and is rich in CRH-expressing neuronal populations, many of
which possess features of local-circuit neurons (24, 25). Activa-
tion of these neuronal populations in the CEA may alter anxiety,
fear, or attentional processes (7, 26, 27), thereby indirectly
affecting memory processes. Additionally, CRH-induced activa-
tion of neurons in the CEA may affect memory through influ-
ences on the hypothalamic–pituitary–adrenocortical axis (28–
30). Also, importantly, it is not known from previous studies
whether endogenous CRH, released in the amygdala during
aversive training, is involved in mediating emotional arousal
effects on memory consolidation.
The experiments reported here investigated the role of en-
dogenous CRH in stress-influenced memory consolidation in-
volving specific amygdala nuclei. In experiments in which mi-
croinfusions of the CRH receptor antagonist [9–41]--helical
CRH were used, we investigated the effects of immediate
posttraining blockade of CRH receptors in either the BLA or the
CEA on retention of inhibitory avoidance training. Other groups
of rats received delayed infusions (i.e., 3 h after training) of the
CRH receptor antagonist into the BLA to examine whether
CRH receptor antagonism specifically influenced memory con-
solidation. The CEA is a likely source of endogenous CRH
activating CRH receptors in the BLA. In view of evidence that
release of CRH from peptidergic neurons in the CEA is in-
creased by single (31, 32) or repeated episodes of restraint stress
(33), we also examined whether a single, brief aversive stimulus
of mild footshock, used in the present experiments, increased
CRH immunoreactivity in the CEA.
Methods
Animals. Male Sprague–Dawley rats (n  188; 270–300 g at time
of surgery) from Charles River Breeding Laboratories were
used. They were housed individually in a temperature-controlled
(22°C) vivarium room and maintained on a standard 12-h
light12-h dark cycle (lights on: 7 a.m. to 7 p.m.), with food and
water available ad libitum. Training and testing were performed
between 10 a.m. and 3 p.m. All methods used were in compliance
with National Institutes of Health guidelines and were approved
by the University of California at Irvine’s Institutional Animal
Care and Use Committee.
Surgery. The animals were adapted to the vivarium for 1 week
before surgery. They were anesthetized with sodium pentobar-
bital (50 mgkg, i.p.) and given atropine sulfate (0.4 mgkg, i.p.)
to maintain respiration. They subsequently were injected with 3.0
ml of saline to facilitate clearance of these drugs and prevent
dehydration. The skull was positioned in a stereotaxic frame
(Kopf Instruments, Tujunga, CA), and stainless-steel guide
cannulae (15 mm; 23 gauge) were implanted bilaterally with the
cannula tips 2 mm above the BLA [coordinates: anteroposterior,
2.8 mm from bregma; mediolateral, 5.0 mm from midline;
dorsoventral, 6.5 mm from skull surface] or the CEA [coor-
dinates: anteroposterior, 2.2 mm; mediolateral, 4.3 mm;
dorsoventral, 6.0 mm] according to the atlas of Paxinos and
Watson (34). Stylets (15-mm-long 00 insect dissection pins) were
Abbreviations: BLA, basolateral complex of the amygdala; CEA, central nucleus of the
amygdala; CRH, corticotropin-releasing hormone.
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inserted into the cannulae to maintain patency and were re-
moved only for the infusion of drugs. Rats were allowed to
recover 7 days before initiation of training and were handled
three times for 1 min each during this recovery period.
Inhibitory Avoidance Apparatus and Procedure. Rats were trained
and tested in an inhibitory avoidance apparatus consisting of a
trough-shaped alley (91 cm long, 15 cm deep, 20 cm wide at the
top, 6.4 cm wide at the floor) divided into two compartments
separated by a sliding door that opened by retracting into the
floor. The starting compartment (31 cm) was made of opaque,
white plastic and well lit; the shock compartment (60 cm) was
made of dark, electrifiable metal plates and was not illuminated.
Training and testing were conducted in a sound- and light-
attenuated room.
The rat was placed in the starting compartment of the
apparatus, facing away from the door, and was allowed to enter
the dark (shock) compartment. As the rat stepped completely
into the dark compartment, the door was closed and a single,
inescapable footshock was delivered. For the first experiment,
two footshock levels were used (i.e., 0.55 mA for 1.0 s or 0.60 mA
for 1.5 s) to determine whether drug effects on retention
performance were experience-dependent. For all other experi-
ments, the higher footshock condition was used. The rat was
removed from the shock compartment 15 s after shock termi-
nation and, after drug treatment, returned to its home cage. On
the retention test 48 h after training, the rat was placed in the
starting compartment, as in the training session, and the latency
to reenter the dark compartment with all four paws (maximum
latency of 600 s) was recorded (note: no shock was administered
on the retention test). Longer latencies were interpreted as
indicating better retention. Extensive evidence indicates that
avoidance of the shock area indicates specific memory of the
place where shock had been received (35, 36).
Drug and Infusion Procedures. Rats received bilateral infusions of
saline or the CRH receptor antagonist [9–41]--helical CRH
(Bachem; 0.3, 1.0, or 3.0 g) into either the BLA or the CEA.
Experimental doses were selected based on previous experi-
ments (33, 37). The infusions were made by using 30-gauge
injection needles connected to a 10-l Hamilton microsyringe by
polyethylene tubing. The injection needle protruded 2 mm
beyond the cannula tip to reach either the BLA or the CEA. A
0.2-l injection volume per hemisphere was infused over a
period of 25 s by an automated syringe pump (Sage Instruments,
Boston). The injection needles were retained within the cannu-
lae for an additional 20 s after drug infusion to maximize
diffusion. The infusion volume was based on findings that drug
infusions of this volume into either the BLA or the CEA induce
differential effects on memory consolidation (38, 39).
Histology. Rats were anesthetized with sodium pentobarbital
(100 mgkg, i.p.) and perfused intracardially with 0.9% saline
followed by 4% formaldehyde. Brains were removed and placed
in 4% formaldehyde, followed by cryoprotection by using a 20%
sucrose solution. Sections of 40 m were cut on a freezing
microtome and stained with cresyl violet. Determination of the
location of the infusion needle tips was made according to
standardized atlas plates of Paxinos and Watson (34). Only rats
with infusion needle tips within the boundaries of the targeted
nucleus were included in the data analysis. Sixty animals were
excluded from further analysis because of either cannula mis-
placement or extensive tissue damage.
Immunocytochemistry. Brains were harvested 30 min after inhib-
itory avoidance training with the higher intensity footshock (i.e.,
0.60 mA for 1.5 s). Control brains were harvested under rela-
tively stress-free conditions (40, 41). Briefly, rats (n 4 for each
group) were left undisturbed for 24 h before experiments and
then were deeply anesthetized with sodium pentobarbital (50
mgkg, i.p.) within 45 s of entry into the animal facility.
Anesthetized rats were removed to the laboratory and perfused
by using 0.9% saline followed by fresh 4% paraformaldehyde in
0.1 M sodium phosphate buffer (PB; pH 7.4, 4°C). Brains were
cryoprotected and stored as described (20, 41) and then sec-
tioned coronally into 50-m-thick slices by using a cryostat. For
neuroanatomic orientation, adjacent sections were stained with
cresyl violet. Adjacent series also were processed for immuno-
cytochemistry for parvalbumin (1:10,000; Chemicon), because
parvalbumin fibers are not found in the CEA.
The immunocytochemistry procedure followed established
protocols that use free-floating sections (20, 41). Briefly, after
several washes with 0.01 M PBS containing 0.3% Triton X-100
(PBS-T) (pH 7.4), sections were treated for 30 min in 0.3%
H2O2PBS, followed by blockade of nonspecific sites with 2%
normal goat serum in PBS for 30 min. After rinsing, sections
were incubated for 36 h at 4°C with rabbit anti-CRH antiserum
(1:60,000; a gift from W. W. Vale, The Salk Institute, La Jolla,
CA) in 0.01 M PBS-T and 1% BSA and 2% normal goat serum
and washed in 0.01 M PBS-T (3  5 min). Sections were
incubated in biotinylated goat-anti-rabbit IgG (1:300; Vector
Laboratories) in 0.01 M PBS-T for 1 h at room temperature.
After washing (3  5 min), sections were incubated in the
avidin–biotin–peroxidase complex solution (1:100; Vector Lab-
oratories) for 2 h and rinsed (3  5 min), and the reaction
product was visualized by incubating the sections in 0.04%
3,3-diaminobenzidine containing 0.01% H2O2.
Statistics. Inhibitory avoidance retention latencies were analyzed
with one- or two-way ANOVAs, followed by Fisher’s post hoc
tests to determine the source of the significance. A probability
level of less than 0.05 was accepted as statistical significance.
Results
Immediate Posttraining Infusions of a CRH Receptor Antagonist into
the Basolateral Amygdala Impair Retention. Immediate posttraining
infusions of the CRH receptor antagonist [9–41]--helical CRH
administered into the BLA impaired retention of inhibitory
avoidance training by using two footshock levels. Average en-
trance latencies during training, before shock exposure, were
12.2  0.7 s (mean  SEM), and a two-way ANOVA indicated
that these training latencies did not differ among the several
posttraining treatment groups [F(3,80)  0.57; P  0.64; data not
shown]. Latencies on the 48-h retention test of rats infused with
saline were longer compared with their training latencies, in both
the lower and higher footshock-level groups, indicating that the
rats retained memory of the shock training (paired t tests: P 
0.05 and P 0.005, respectively). As shown in Fig. 1A, immediate
posttraining intra-BLA infusions of the CRH receptor antago-
nist [9–41]--helical CRH induced dose-dependent retention
impairment in both the lower and higher footshock-level groups.
Two-way ANOVA of retention latencies revealed a significant
CRH receptor antagonist effect [F(3,80)  3.83; P  0.05], a
significant footshock-level effect [F(1,80)  30.67; P  0.0001],
and an insignificant interaction between both factors [F(3,80) 
1.75; P 0.16]. As expected, retention latencies of saline-infused
rats after training with the higher footshock level were signifi-
cantly longer than those of saline-infused rats trained with the
lower footshock (P 0.005). Retention latencies of rats given the
highest dose of [9–41]--helical CRH (3.0 g) were impaired
significantly compared with those of rats given saline infusions
(lower footshock level, P  0.05; higher footshock level, P 
0.005).
To examine whether retention impairment induced by imme-
diate posttraining administration of [9–41]--helical CRH was
due to influences on consolidation processes, the antagonist
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(3.0 g) was infused 3 h after inhibitory avoidance training in a
separate group of rats. As shown in Fig. 1B, 48-h retention
latencies of rats given [9–41]--helical CRH (3.0 g) into the
BLA 3 h after training (0.60 mA, 1.5 s) did not differ from those
of rats given saline infusions 3 h after training (P  0.92).
Immediate Posttraining Infusions of a CRH Receptor Antagonist into
the Central Amygdala Do Not Affect Retention. In view of the high
density of CRH-producing neurons in the CEA (25), the precise
site of action of endogenous CRH to enhance memory retention
required elucidation. Therefore, we examined whether infusions
of [9–41]--helical CRH administered into the CEA immedi-
ately after training (0.60 mA, 1.5 s) impaired inhibitory avoid-
ance retention. As shown in Fig. 1C, retention latencies of rats
given immediate posttraining infusions of [9–41]--helical CRH
(3.0 g) into the CEA did not differ from those of rats given
saline infusions (P  0.89). The precise neuroanatomic location
of the CEA and BLA infusion sites, supporting the differential
effects of the CRH receptor antagonist, are shown in Fig. 2.
Endogenous CRH Is Released During Inhibitory Avoidance Training.
Whereas the previous experiments clearly indicated that CRH
does not act within the CEA to influence memory consolidation,
the CEA contains a large group of CRH-expressing neurons. In
addition, the proximity of the CEA and the BLA raised the
possibility that CRH acting on receptors in the BLA originated
in CEA peptidergic neurons and diffused relatively long dis-
tances (42). To examine whether inhibitory avoidance training
with administration of a single, brief footshock (0.60 mA, 1.5 s)
increases CRH levels in the CEA, we performed immunocyto-
chemical analysis of CRH, focusing on cells, terminals, as well as
‘‘free’’ immunoreactive peptide in the neuropil of these two
amygdala nuclei.
In stress-free animals (not subjected to training or footshock;
see Methods), levels of ‘‘extracellular’’ immunoreactive CRH,
not confined to cell bodies or processes, were low and contained
within the neuroanatomical boundaries of the CEA (Fig. 3 B and
D). In animals killed 30 min after the aversive training stimulus,
an increase of immunoreactive extracellular CRH was found
(Fig. 3 A and C). The BLA was delineated by using Nissl stain
(Fig. 3E) and augmented by parvalbumin immunoreactivity (Fig.
3F and ref. 43).
Discussion
The major finding of these experiments is that immediate
posttraining infusions of the CRH receptor antagonist [9–41]-
-helical CRH administered into the BLA, but not the adjacent
CEA, induced dose-dependent inhibitory avoidance retention
impairment. The use of posttraining infusion techniques ex-
cludes the possibility that the CRH receptor antagonist infusions
altered retention by influences on anxiety, fear, locomotor
activity, or attentional processes during acquisition (44, 45),
effects of CRH that have been ascribed to the amygdala (26, 27,
46–48). The present study also demonstrates that infusions of
[9–41]--helical CRH into the BLA impaired retention perfor-
mance only when administered shortly after training. These
findings strongly support the hypothesis that the antagonist
infusions into the BLA interfered with the consolidation of
long-term memory. A selective involvement of the BLA in
mediating CRH receptor antagonist effects on memory consol-
idation is consistent with previous evidence indicating that
Fig. 1. Step-through latencies (mean SEM) in seconds on a 48-h inhibitory avoidance retention test. (A) Rats given immediate posttraining infusions of saline
or [9–41]--helical CRH (0.3, 1.0, or 3.0 g in 0.2 l) into the BLA after training with either a low (0.55 mA, 1.0 s) or high footshock level (0.60 mA, 1.5 s). (B) Rats
given infusions of saline or [9–41]--helical CRH (3.0 g in 0.2 l) into the BLA 3 h after training (0.60 mA, 1.5 s). (C) Rats given immediate posttraining (0.60 mA,
1.5 s) infusions of saline or [9–41]--helical CRH (3.0 g in 0.2 l) into the CEA. *, P  0.05; **, P  0.01 as compared with the corresponding saline group
(n  7–13 per group).
Fig. 2. Representative photomicrographs illustrating placement of cannulae
in the BLA (A) or the CEA (B). OT, optic tract.
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posttraining infusions of drugs affecting several other hormonal
or neurotransmitter systems, including adrenergic, glucocorti-
coid, and GABAergic systems, also affected memory only when
administered into the BLA (39, 49, 50). Similarly, lesions of the
BLA, but not the CEA, block memory modulation induced by
systemic drug injections (51, 52).
Our finding that pharmacological inhibition of CRH receptors
in the BLA impaired retention performance suggests that the
antagonist prevented endogenous CRH from influencing mem-
ory consolidation. On the basis of the observation that the CRH
receptor antagonist impaired retention performance irrespec-
tive of whether rats were trained on a low or high footshock level,
it appears that CRH receptors in the BLA are stimulated either
by mildly aversive training conditions or that they are tonically
activated. Stress-induced increases in amygdalar CRH were
found previously with more severe stressors such as single or
repeated restraint (31, 32, 47). The present findings demon-
strated that inhibitory avoidance training with a single, brief
footshock markedly increased CRH immunoreactivity in the
CEA, findings that support the hypothesis that CRH, released by
the aversive training condition, participates in mediating stress
effects on memory consolidation. It should be noted that within
the amygdala, CRH mRNA-expressing cells and CRH-
immunoreactive somata generally are confined to the CEA (25),
where they comprise a large and heterogeneous neuronal pop-
ulation (24). Whereas the current experiments pinpoint the site
of action (i.e., receptor activation) of endogenous amygdalar
CRH, they do not distinguish between two possible release
mechanisms of the peptide. CRH might be released within the
CEA by the stressful training stimulus and travel to the BLA,
consistent with the documented transport of exogenous peptide
for long distances within the brain (42). The alternative possi-
bility, that axon terminals of neurons located in the CEA might
reach the BLA, releasing the peptide in close proximity to
receptor-bearing target neurons, is not supported by anatomical
studies (53).
If CRH diffuses from the CEA to the BLA, why was this not
observed with the antagonist, which did not impair inhibitory
avoidance retention when infused into the CEA? Findings have
demonstrated that the [9–41]--helical CRH molecule is much
less diffusible in aqueous tissues compared with CRH. Whereas
ready diffusion of CRH from the lateral cerebral ventricle to the
amygdala clearly has been demonstrated (42, 54), the less soluble
antagonist would be far less diffusible (reviewed in ref. 55). In
addition, the doses of antagonist infused into the CEA were
sufficient to block all endogenous CRH: ratios of 6:1 to 12:1 of
the CRH antagonist to the native peptide are required for fully
antagonizing the central actions of CRH (56). Because the
amounts of CRH in the CEA (0.62 ngmg protein) are lower
than 1 ng (57), the 0.3 g of [9–41]--helical CRH infused into
the CEA was ample to antagonize all local actions of native
CRH.
Extensive evidence is consistent with a role of CRH in
mediating stress effects on memory consolidation (refs. 8, 12, 15,
58, and 59; for a review, see ref. 60), but effects on memory
retrieval also have been reported (37, 61). Furthermore, elec-
trophysiological studies in hippocampal slices have shown that
exogenous CRH application facilitates long-term potentiation
(15, 62, 63) and that a CRH receptor antagonist blocks stress-
induced facilitation of hippocampal long-term potentiation (15).
Moreover, CRH produces a long-lasting enhancement of syn-
aptic efficacy in the rat hippocampus in vivo (64, 65) and
enhances protein synthesis (10). Previous evidence that post-
training infusions of a large volume of exogenous CRH into the
amygdaloid complex enhanced memory consolidation for inhib-
itory avoidance training (22) is also compatible with our findings
and suggests that CRH modulates amygdala influences on
memory consolidation. Other studies have implicated CRH in
the amygdala in reward-related learning. Local infusions of
[9–41]--helical CRH or injections of a CRH antibodytoxin
mixture into the amygdala reversed the negative motivational
consequences of morphine withdrawal in a place-conditioning
paradigm and in a conditioned operant suppression task in rats
(66). Although that study did not aim specifically at the BLA,
other studies reported that selective BLA lesions abolish the
ability of drug-associated cues to reinstate responding during
withdrawal from self-administered cocaine (67), supporting the
view that the BLA may have been the site of action of CRH.
Furthermore, Ambrosio et al. (68) reported a large reduction in
CRF1-binding sites in the BLA after chronic cocaine adminis-
tration. Several recent findings have suggested an involvement of
CRF1 receptors in learning and memory functions (12). The
BLA is particularly rich in CRF1 receptors (20, 69). Thus,
although [9–41]--helical CRH is a nonspecific CRH receptor
antagonist, which can bind to both CRF1 and CRF2 receptors,
the memory impairments found in the present study may have
been mediated selectively by a blockade of CRF1 receptors.
Fig. 3. CRH is released from CEA neurons after footshock administration in
an inhibitory avoidance task. Extracellular immunoreactive CRH in the CEA of
rats killed 30 min after receiving the higher-intensity footshock (0.60 mA, 1.5 s)
is enhanced (A and C) compared with stress-free controls (B and D) and
appears to invade the BLA. Boundaries of the BLA are delineated using Nissl
stain (E). Further illustration of the parvalbumin (PV)-free CEA is provided (F);
note that only a portion of the lateral nucleus (La) expresses PV. Overlay
is according to Paxinos and Watson (34). [Bar  350 m (A, B, E, and F) and
150 m (C and D).]
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Several studies examining CRH effects in brain regions other
than the BLA have indicated an intimate relationship with the
noradrenergic system, affecting anxiety, arousal, and attention
(70–74). These effects appear to be mediated by the CRF1
receptor (73). CRH–noradrenergic interactions also play a role
in memory: the -adrenoceptor antagonist propranolol or the
noradrenergic toxin DSP-4 blocks memory enhancement in-
duced by CRH infusions into the hippocampus (75). These
findings would suggest that CRH, through a presynaptic facili-
tation mechanism, stimulates the release of norepinephrine in
the hippocampus (76). Moreover, both the -adrenoceptor and
CRH receptor are coupled to the adenylate cyclase system
(77–79), providing an additional potential locus of interaction at
the postsynaptic level. These findings are highly relevant to CRH
effects on memory modulation in the BLA because extensive
evidence has demonstrated a central role for norepinephrine in
the BLA in memory modulation. Stressful stimulation, including
inhibitory avoidance training, induces the release of norepineph-
rine in the amygdala (80–82), whereas posttraining infusions of
norepinephrine or -adrenoceptor agonists administered into
the BLA enhance memory consolidation (50, 83, 84). Further-
more, blockade of noradrenergic mechanisms in the BLA with
a -adrenoceptor antagonist prevents memory enhancement
induced by systemic or intra-BLA administration of a glucocor-
ticoid receptor agonist (84, 85). These findings lend support for
the view that CRH, perhaps via an interaction with glucocorti-
coids (86, 87), may interact with the noradrenergic system of the
BLA in influencing memory consolidation.
In summary, the present findings show that [9–41]--helical
CRH impairs memory consolidation when administered into the
BLA immediately after training. These findings suggest that
acute stress induces rapid CRH release from CEA neurons and
activation of CRH receptors on BLA neurons involved in
modulating memory consolidation. This stress-activated mech-
anism serves the adaptive function of influencing the consoli-
dation of strong, long-lasting memories of emotionally signifi-
cant experiences.
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